According to the latest research by Nova one advisor, the global Proteomics market is valued at USD 27.95 Billion in 2024, and it is expected to reach USD 95.81 Billion by 2034, with a CAGR of 13.11% during the forecast period of 2024-2034.
Proteomics Market Key Takeaways:
· North America dominated the market and accounted for 46.0% revenue share in 2024.
· The reagents & consumables segment accounted for the largest revenue share of 72.29% in 2024.
· The services segment is projected to grow at the fastest CAGR from 2024 to 2034.
· The spectrometry segment captured the largest revenue share in 2024. It is also expected to expand further at the highest CAGR of 14.77% during the forecast period.
· The next-generation sequencing (NGS) segment is projected to grow at a significant pace from 2024 to 2034.
· The drug discovery segment dominated the proteomics market with the largest revenue share of 53.0% in 2024.
· The clinical diagnostics segment is expected to experience the fastest CAGR during the forecast period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/7577
U.S. Proteomics Market Size and Growth 2024 to 2034
The U.S. proteomics market size is evaluated at USD 10.5 billion in 2024 and is projected to be worth around USD 32.32 billion by 2034, growing at a CAGR of 11.9% from 2024 to 2034.
North America dominated the market and accounted for 46.0% revenue share in 2024. The market growth in the region is attributed to the highly advanced healthcare infrastructure, rising government funding for healthcare research and biotechnology, and substantial research and development investments in precision medicine. In addition, increasing demand for advanced disease diagnostics and growing advancements in technology.
The U.S. is dominated the market share in 2024. The market growth in the U.S. is attributed to the increasing presence of key players in the country, rising technological advancements & innovation in mass spectrometry in biotechnology and medicine research, and increasing robust research and development activities in life sciences and biotechnology.
Asia Pacific proteomics market is anticipated to witness the fastest CAGR of 15.97% from 2024 to 2034. The proteomics market growth in the region is driven by the increasingly strong presence of biopharmaceutical and biotechnology companies, favourable government regulations, and an increasing preference for outsourcing proteomics-based projects. In addition, the increasing private and public funding for research and development for proteomics studies and increasing prevalence of chronic diseases.
The market growth in the country is attributed to the rise of government investment in research activities and the increasing presence of biopharmaceutical companies included in drug development and discovery are expected to drive the growth of the proteomics market in India.
· For instance, in November 2024, IIT Bombay hosted a symposium titled “Pioneering the Future of Healthcare and Diagnostics Using 4D Omics”. The event was organized by the Proteomics Lab, Department of Biosciences and Bioengineering (BSBE) which showcased groundbreaking advancements in 4D-proteomics and 4D omics. The aim behind this launch was to revolutionize diagnostics and personalized healthcare
Proteomics market deals with the study of large-scale proteomics. Proteomics are a whole complement of proteins expressed by organisms, cells, or tissue. Proteomics aims to interpret the roles of a huge number of proteins made by combining 22 genetically encoded amino acids. Proteomics helps to understand the interactions, function, and structure of the entire protein content in a particular organism. In addition, it is used to investigate protein expression, modification of protein, degradation, and rates of protein production.
The increasing government initiatives to improve research and development in bioinformatics, genomics, and proteomics, rising technological advancements in protein analysis, and increasing prevalence of infectious and chronic diseases are expected to drive the growth of the proteomics market.
One of the major opportunities driving the market is the adoption of advanced high-throughput technologies, such as multi-omics approaches and next-generation mass spectrometers. These technologies enable more comprehensive studies of protein functions and interactions and allow researchers to conduct high-throughput analysis. Furthermore, developments in software tools and sample analysis methods for data analysis have streamlined workflows, which further transform the growth of the proteomics market.
Artificial intelligence can play an important role in improving genomics. AI has emerged as a prediction in proteomics, pattern recognition, and enhancing data processing. AI provides various advantages in interpreting and analyzing proteomics data. AI models analyze structural and sequence data to infer protein functions. AI helps to identify functional domains within proteins and helps in understanding their roles in biological processes. In addition, the adoption of AI in proteomics is rapidly evolving, with promising avenues for future research, which is expected to revolutionize the growth of the proteomics market.
Proteomics Market Trends
· Rising demand for personalized medicine: By providing insights at the molecular level, proteomics play a vital role in personalized medicine. This makes it possible to implement targeted therapies to support individualized medicine through follow-up of therapy responses, identification of drug targets, and biomarker discovery.
· Increasing emphasis on products: The increasing emphasis on product attributes in clinical diagnostics, biomarker discoveries, and drug design for treating and diagnosing and treating diseases is expected to drive the growth of the proteomics market.
Proteomics Market Report Scope
|
Report Attribute |
Details |
|
Revenue forecast in 2025 |
USD 31.61 Billion |
|
Revenue forecast in 2034 |
USD 95.81 Billion |
|
Growth rate |
CAGR of 13.11% from 2024 to 2034 |
|
Actual data |
2019 - 2024 |
|
Forecast period |
2024 - 2034 |
|
Report updated |
December 2024 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2034 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product & Services, Application, Technology, Region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Bruker Corporation; F. Hoffmann-La Roche Ltd.; Waters Corporation; Merck KGaA; Danaher; Standard BioTools Inc. |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Segment Insights By Product & Service Insights The reagents & consumables segment
accounted for the largest revenue share of 72.29% in 2024. Reagents for
proteomics assays help identify novel biomarkers
crucial for early disease diagnosis, especially in diseases such as
cardiovascular diseases, Alzheimer and cancer. Kits designed for mass
spectrometry allow researchers to analyze proteins within complicated
biological samples efficiently. The services segment is expected to grow
fast during the forecast period. The segment growth is attributed to the rising
advanced technologies in protein analysis and increasing demand for specialized
expertise. Many organizations outsource tasks such as data analysis, protein
identification, and mass spectrometry, as proteomics research becomes more
complex. In addition, the increasing adoption of biomarker discovery and personalized
medicine is further expected to drive the segment growth. By Technology Insights The spectrometry segment dominated the
proteomics market. The segment growth is attributed to the rising advancements
in mass spectrometry technology including increased automation, speed, and
resolution, and the integration of spectrometry
techniques with bioinformatics
data analysis. Spectrometry technology is used for the characterization and
identification of proteins, analysis of protein-protein interactions, and
detection of post-translational modifications. ·
For instance, in December 2024, Roche announced that it had received CE mark
approval for its cobas® Mass Spec solution such as the cobas® i 601 analyzers
and the first Ionify® reagent pack of four assays for steroid hormones2. The next-generation
sequencing segment is expected to grow fastest during the forecast
period. The segment growth in the proteomics market is attributed to the
growing adoption of companion personalized
medicine and diagnostics, the rising technological advancements in next
generation sequencing, and the rising usage of NGS for liquid biopsy. ·
For instance, in January 2025, Illumina, Inc., a global
leader in DNA
sequencing and array-based technologies, announced a pilot
proteomics program to analyze 50,000 UK Biobank samples in collaboration with
Johnson & Johnson, powered by SOMAmer® technology, a next-generation
sequencing (NGS). By Application Insights The drug
discovery segment dominated the proteomics market with the largest
revenue share of 53.0% in 2024. The segment growth in the proteomics
market is driven by increased investments in these areas, a greater
significance on creating personalized drugs, and the development of
structure-based drug design. In addition, leading to ultimately benefiting
healthcare systems and patients and significant cost savings for pharmaceutical
companies, proteomics technologies offer an early indication of a drug's
potential in the discovery process, thus propelling the segment's growth. The clinical diagnostics segment is
expected to grow fastest during the forecast period. The segment growth is
driven by the increasing adoption of protein analysis among clinical
researchers to identify individual risk factors and biomarkers
for early disease detection. Furthermore, it is possible to uncover protein
expression patterns and potential biomarkers,
with the help of proteomics-based diagnosis that can be used to predict and
classify tumors, which further drive segment growth. Immediate Delivery is Available | Get
Full Report Access@ https://www.novaoneadvisor.com/report/checkout/7577
Related Report Some of the prominent players in the
proteomics market include: ·
Thermo Fisher Scientific, Inc. ·
F. Hoffmann-La Roche Ltd. ·
Waters Corporation ·
Merck KGaA ·
Danaher Proteomics Market Recent Developments ·
In January 2025,
with the promise of delivering a "transformation" in the study of
diseases and their treatments, a major population proteomics study using UK
Biobank patient samples was launched by 14 pharma companies. ·
In January 2025,
Quantum-Si Incorporated, the protein sequencing company announced the launch of
Platinum® Pro, its latest benchtop sequencer that sets a new standard in
protein analysis. The aim behind this launch was to redefine versatility and
efficiency in proteomics research. ·
In October 2024,
SCIEX, with the launch of the ZenoTOF 7600+ system accompanied by three new
collaborations advancing proteomics capabilities, SCIEX, a global leader in
life science analytical technologies advances its high-resolution accurate mass
spectrometry portfolio. Segments Covered in the Report This report forecasts revenue growth at
country levels and provides an analysis of the latest industry trends in each
of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc.
has segmented the proteomics market By Product & Services ·
Instruments ·
Reagents & Consumables ·
Services By Application ·
Drug Discovery ·
Clinical Diagnostics ·
Others By Technology ·
Next-generation Sequencing ·
Microarray Instruments ·
X-Ray Crystallography ·
Spectrometry ·
Chromatography ·
Protein Fractionation Systems ·
Electrophoresis ·
Surface Plasma Resonance (SPR) Systems ·
Other Technologies By Regional ·
North America ·
Europe ·
Asia Pacific ·
Latin America ·
Middle East and Africa (MEA) Immediate Delivery Available | Buy This
Premium Research https://www.novaoneadvisor.com/report/checkout/7577
USA: +1 804 441 9344 APAC: +61 485 981 310 or +91 87933 22019 Europe: +44 7383 092 044 Email: sales@novaoneadvisor.com Web: https://www.novaoneadvisor.com/
You can place an order or ask any
questions, please feel free to contact at sales@novaoneadvisor.com |
+1 804 441 9344